Mycobacterial pulmonary infections in patients with idiopathic pulmonary fibrosis

Journal of Korean Medical Science

Volumn 27, Issue 8, 2012, Pages 896-900

  Park, Sung Woo ^a   Song, Jin Woo ^b   Shim, Tae Sun ^b   Park, Moo Suk ^c   Lee, Hong Lyeol ^d   Uh, Soo Taek ^a   Park, Choon Sik ^a   Kim, Dong Soon ^b  

^a Soonchunhyang University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Inha University School of Medicine   (South Korea)

Author keywords

Idiopathic pulmonary fibrosis; Immunosuppressants; Korea; Mycobacterium tuberculosis; Nontuberculous mycobacteria

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

AGED; ARTICLE; ATYPICAL MYCOBACTERIOSIS; COHORT ANALYSIS; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; LUNG TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIOSIS; PATHOLOGY; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL;

AGED; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; RETROSPECTIVE STUDIES; TUBERCULOSIS, PULMONARY;

EID: 84866515324     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2012.27.8.896     Document Type: Article

References (40)

1. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-51.
2. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810-6.
3. Scientific Committee of the Korean Academy of Tuberculosis and Respiratory Diseases. 2008 National Survey of Idiopathic Interstitial Pneumonia in Korea. Tuberc Respir Dis 2009; 66: 141-51.
4. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162: 2213-7.
5. Gay SE, Kazerooni EA, Toews GB, Lynch JP 3rd, Gross BH, Cascade PN, Spizarny DL, Flint A, Schork MA, Whyte RI, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157: 1063-72.
6. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-81.
7. Ask K, Martin GE, Kolb M, Gauldie J. Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls. Proc Am Thorac Soc 2006; 3: 389-93.
8. Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88: 396-404.
9. Saydain G, Islam A, Afessa B, Ryu JH, Scott JP, Peters SG. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med 2002; 166: 839-42.
10. Tang YW, Johnson JE, Browning PJ, Cruz-Gervis RA, Davis A, Graham BS, Brigham KL, Oates JA Jr, Loyd JE, Stecenko AA. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol 2003; 41: 2633-40.
11. Jeon K, Chung MP, Lee KS, Chung MJ, Han J, Koh WJ, Suh GY, Kim H, Kwon OJ. Prognostic factors and causes of death in Korean patients with idiopathic pulmonary fibrosis. Respir Med 2006; 100: 451-7.
12. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization, 1991. Bull World Health Organ 2001; 79: 71-5.
13. Falkinham JO 3rd. Nontuberculous mycobacteria in the environment. Clin Chest Med 2002; 23: 529-51.
14. Marras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med 2002; 23: 553-67.
15. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367-416.
16. Scientific Committee in Korean Academy of Tuberculosis and Respiratory Diseases. National survey of mycobacterial diseases other than tuberculosis in Korea. Tuberc Respir Dis 1995; 42: 277-94.
17. Shachor Y, Schindler D, Siegal A, Lieberman D, Mikulski Y, Bruderman I. Increased incidence of pulmonary tuberculosis in chronic interstitial lung disease. Thorax 1989; 44: 151-3.
18. Chung MJ, Goo JM, Im JG. Pulmonary tuberculosis in patients with idiopathic pulmonary fibrosis. Eur J Radiol 2004; 52: 175-9.
19. Park S, Suh GY, Chung MP, Kim H, Kwon OJ, Lee KS, Lee NY, Koh WJ. Clinical significance of Mycobacterium fortuitum isolated from respiratory specimens. Respir Med 2008; 102: 437-42.
20. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-64.
21. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva: WHO, 2010.
22. Diagnosis and treatment of disease caused by nontuberculous ycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997; 156: S1-25.
23. World Health Organization. Global Tuberculosis Control: Surveillance, Planing, Financing: WHO report 2006.
24. Horsburgh CR Jr. Epidemiology of Mycobacterium avium complex. In: Korvick JA, Benson CA, editors. Mycobacterium avium complex infection: progress in research and treatment. New York: Marcel Dekker, 1996. p 1-22.
25. Raju B, Schluger NW. Significance of respiratory isolates of Mycobacterium avium complex in HIV-positive and HIV-negative patients. Int J Infect Dis 2000; 4: 134-9.
26. Hansen LA, Prakash UB, Colby TV. Pulmonary complications in diabetes mellitus. Mayo Clin Proc 1989; 64: 791-9.
27. Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38: 1428-39.
28. O'Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. Am Rev Respir Dis 1987; 135: 1007-14.
29. Olivier KN, Weber DJ, Wallace RJ Jr, Faiz AR, Lee JH, Zhang Y, Brown-Elliot BA, Handler A, Wilson RW, Schechter MS, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 828-34.
30. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147: 1271-8.
31. Middleton AM, Chadwick MV, Nicholson AG, Dewar A, Groger RK, Brown EJ, Ratliff TL, Wilson R. Inhibition of adherence of Mycobacterium avium complex and Mycobacterium tuberculosis to fibronectin on the respiratory mucosa. Respir Med 2004; 98: 1203-6.
32. Morrissey BM. Pathogenesis of bronchiectasis. Clin Chest Med 2007; 28:289-96.
33. Mycobacterioses and the acquired immunodeficiency syndrome. Joint Position Paper of the American Thoracic Society and the Centers for Disease Control. Am Rev Respir Dis 1987; 136: 492-6.
34. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
35. Keane J. Tumor necrosis factor blockers and reactivation of latent tuberculosis. Clin Infect Dis 2004; 39: 300-2.
36. Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992; 166:405-12.
37. Ingram CW, Tanner DC, Durack DT, Kernodle GW Jr, Corey GR. Disseminated infection with rapidly growing mycobacteria. Clin Infect Dis 1993; 16: 463-71.
38. Horsburgh CR Jr, Mason UG 3rd, Farhi DC, Iseman MD. Disseminated infection with Mycobacterium avium-intracellulare. A report of 13 cases and a review of the literature. Medicine (Baltimore) 1985; 64: 36-48.
39. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161: S221-47.
40. Hong YP. Tuberculosis in Korea-yesterday, today and tomorrow. Tuberc Respir Dis 1997; 44: 1-10.